Quantifying the impact of immunotherapy on RNA dynamics in cancer

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy

(2023) Caleb Gonzalez et al.   Communications Biology

Local γδ T cells: translating promise to practice in cancer immunotherapy

(2023) Iva Zlatareva et al.   BRITISH JOURNAL OF CANCER

Genomic–transcriptomic evolution in lung cancer and metastasis

(2023) Carlos Martínez-Ruiz et al.   NATURE

Immune-checkpoint inhibitors: long-term implications of toxicity

(2022) Douglas B. Johnson et al.   Nature Reviews Clinical Oncology

Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression

(2022) Donghwan Jeon et al.   OncoImmunology

IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer

(2022) Olga S. Blomberg et al.   CANCER CELL

Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer

(2021) Wen Tan et al.   BMC CANCER

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

(2021) Kevin Litchfield et al.   CELL

Knocking out alpha-synuclein in melanoma cells dysregulates cellular iron metabolism and suppresses tumor growth

(2021) Sahar Shekoohi et al.   Scientific Reports

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

(2021) Justina X. Caushi et al.   NATURE

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment

(2021) A. Farias et al.   Scientific Reports

High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers

(2021) Ling Zhang et al.   Frontiers in Oncology

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

(2021) Lewis Au et al.   CANCER CELL

SOX10 Regulates Melanoma Immunogenicity through an IRF4–IRF1 Axis

(2021) Satoru Yokoyama et al.   CANCER RESEARCH

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

(2021) Diego Chowell et al.   NATURE BIOTECHNOLOGY

Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape

(2021) Yoshiko Takeuchi et al.   Science Immunology

MICA and KLRK1 genes and their impact in cervical intraepithelial neoplasia development in the southern Brazilian population

(2020) Renate von Linsingen et al.   HUMAN IMMUNOLOGY

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma

(2020) Benjamin P. Fairfax et al.   NATURE MEDICINE

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

(2020) J.H. Shim et al.   ANNALS OF ONCOLOGY

Super-enhancer acquisition drives oncogene expression in triple negative breast cancer

(2020) Ryan Raisner et al.   PLoS One

Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy

(2020) Shoujian Ji et al.   BIOMEDICINE & PHARMACOTHERAPY

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

(2020) Nick van Dijk et al.   NATURE MEDICINE

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines

(2020) Ji-Eun Park et al.   Journal for ImmunoTherapy of Cancer

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma

(2020) Jeffrey C Thompson et al.   Journal for ImmunoTherapy of Cancer

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

(2019) Sarabjot Pabla et al.   Journal for ImmunoTherapy of Cancer

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy

(2019) Melvyn T. Chow et al.   IMMUNITY

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

(2019) Leonie Voorwerk et al.   NATURE MEDICINE

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

A clonal expression biomarker associates with lung cancer mortality

(2019) Dhruva Biswas et al.   NATURE MEDICINE

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

(2019) Thomas Powles et al.   NATURE MEDICINE

An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer

(2019) Yin Wu et al.   Science Translational Medicine

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

(2019) David Liu et al.   NATURE MEDICINE

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

(2018) Seung Tae Kim et al.   NATURE MEDICINE

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

(2018) David F. McDermott et al.   NATURE MEDICINE

Immunological differences between primary and metastatic breast cancer

(2018) B Szekely et al.   ANNALS OF ONCOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

(2018) Noam Auslander et al.   NATURE MEDICINE

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

(2018) Li Wang et al.   Nature Communications

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

(2018) Leisha A. Emens et al.   JAMA Oncology

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

(2017) Alexandra Snyder et al.   PLOS MEDICINE

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data

(2015) Antonio Colaprico et al.   NUCLEIC ACIDS RESEARCH

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients

(2014) E. Cha et al.   Science Translational Medicine

12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

(2012) Jane L. Messina et al.   Scientific Reports